Product description
Product Overview
Fortune Saffron Ofloxacin Tablets USP 200 mg is a broad-spectrum fluoroquinolone antibiotic formulated to treat a wide range of bacterial infections. It is effective against susceptible gram-positive and gram-negative bacteria and is commonly prescribed for respiratory, urinary tract, gastrointestinal, and skin infections.
This formulation ensures rapid bactericidal action and dependable therapeutic outcomes when administered as directed by healthcare professionals.
Composition
| Component | Strength |
|---|---|
| Ofloxacin USP | 200 mg |
| Excipients | q.s. |
Indications
| Condition | Usage |
|---|---|
| Respiratory tract infections | Bronchitis, pneumonia and ENT infections |
| Urinary tract infections | Acute and chronic UTIs |
| Gastrointestinal infections | Bacterial diarrhea and enteric infections |
| Skin & soft tissue infections | Bacterial skin infections |
| Other susceptible infections | As prescribed by physician |
Key Benefits
- Broad-spectrum antibacterial coverage
- Rapid bactericidal action
- Effective against gram-positive and gram-negative organisms
- Suitable for multiple systemic infections
- Reliable oral antibiotic therapy
Mechanism of Action
- Inhibits bacterial DNA gyrase and topoisomerase IV
- Prevents bacterial DNA replication and repair
- Stops bacterial multiplication
- Leads to rapid elimination of infection
Dosage & Administration
To be taken strictly as directed by a healthcare professional.
| Patient Type | Recommended Dose |
|---|---|
| Adults | 200–400 mg daily in divided doses |
| Severe infections | As prescribed by physician |
| Administration | Take with water, with or without food |
Complete the full course of therapy to prevent antibiotic resistance.
Quality & Presentation
| Parameter | Details |
|---|---|
| Dosage Form | Film-coated tablets |
| Strength | 200 mg |
| Pack Size | Blister packaging |
| Storage | Store below 30°C. Protect from moisture. |
| Manufacturing | Manufactured under GMP-certified facility |
Reviews
There are no reviews yet.